MASTERINVEST Kapitalanlage GmbH Buys 10,108 Shares of Boston Scientific Corporation $BSX

MASTERINVEST Kapitalanlage GmbH boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 20.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,836 shares of the medical equipment provider’s stock after purchasing an additional 10,108 shares during the period. MASTERINVEST Kapitalanlage GmbH’s holdings in Boston Scientific were worth $5,744,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after buying an additional 3,932 shares during the last quarter. State Street Corp increased its position in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the period. Synergy Asset Management LLC increased its position in Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after acquiring an additional 479,593 shares during the period. Bank Pictet & Cie Europe AG raised its stake in shares of Boston Scientific by 75.3% during the second quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock valued at $17,685,000 after acquiring an additional 70,753 shares during the last quarter. Finally, MRA Advisory Group acquired a new position in shares of Boston Scientific during the second quarter worth $273,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 93,095 shares of company stock valued at $9,305,450. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.7%

Shares of BSX stock opened at $97.68 on Friday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock has a 50 day simple moving average of $97.58 and a two-hundred day simple moving average of $100.78. The company has a market cap of $144.80 billion, a P/E ratio of 52.23, a PEG ratio of 1.74 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the subject of a number of recent research reports. Cowen restated a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. BTIG Research reissued a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and a consensus target price of $125.21.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.